Breaking Down Acoramidis OLE Data from HFSA 2023, with Ahmad Masri, MD, MS
HCP Live,
New long-term safety and tolerability data from a phase 2 trial examining acoramidis is providing clinicians additional insight…
New long-term safety and tolerability data from a phase 2 trial examining acoramidis is providing clinicians additional insight…
Loading... The protein transthyretin can misfold and form solid deposits of amyloid.